Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (415)	8/25/1999 10:43:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 626

Suggest that all get a copy of today's Wall Street Journal as they had a feature article today..."New Weapons in the War on Schizophrenia" This was a multi-page article with a lot of information. They nearly "screwed-up" as it relates to TTP as in a chart listing the drugs in the pipeline they associate ILOPERIDONE with Hoechst. However, later in the article they state the following...."Novartis is developing a drug, ZOMARIL, that hits a number of neuro-transmitter targets and is especially intriguing because its effect on the serotonin system appears also to help fight the depression that often exacerbates the illness". No mention of TTP in the article but should lead to more attention to TTP's part in this drug development. Wouldn't be surprised to see some delayed action in the stock.